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Case report
  A 51-year-old Caucasian female initially presented to 
the emergency department in April 2010 with complaints 
of  urinary retention. She had a past medical history signifi-
cant for lupus, hypertension, stage III chronic renal failure, 
multiple painful skin lesions (Figs. 1, 2), and severe uterine 
fibroids requiring hysterectomy at age 23. Ultrasound (US) 
and noncontrast computed tomography (CT) evaluation 
showed a cortically based, partially exophytic mass, involv-
ing the lower pole of  the right kidney, that demonstrated 
peripheral calcifications concerning for neoplasm (Fig. 3). A 
magnetic resonance imaging (MRI) scan performed one 
month later revealed two enhancing lesions in the right 
kidney that were concerning for neoplasm, one of  which 
corresponded to the partially calcified lesion seen on CT.
The patient underwent partial nephrectomy for the right 
renal lesions in October 2010. Pathological exam revealed 
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A 51-year-old Caucasian female presenting with renal-cell cancer and cutaneous leiomyomas was later 
diagnosed with Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome. HLRCC is an 
autosomal dominant condition caused by a mutation in the fumarate hydratase gene, which encodes for 
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cantly increased risk of  developing renal-cell carcinoma, cutaneous leiomyomas, and uterine leiomyo-
mas, and a smaller chance of  developing uterine leiomyosarcomas. This syndrome has a relatively poor 
prognosis, with tumor metastasis occurring in approximately 50% of  patients. However, more aggressive 
prophylactic measures and recent studies have shown potential to improve patient prognosis.
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Figure 1. Two cutaneous leiomyomas visible on the pa-
tient's right arm.
two renal tumors, 2.2 and 1.0 cm in size. The larger 
showed a mixed solid and tubular histologic pattern (Fig. 4). 
Tumor cells were predominantly oncocytic, with abundant 
granular cytoplasm and Furhman grade 3 to 4 nuclei. 
Eosinophilic macronucleoli were present, but perinucleolar 
haloes were inconspicuous. The 1.0-cm tumor displayed 
morphologic features of  type 2 papillary renal-cell carci-
noma (Fig. 5). The surrounding renal tissue showed an ad-
ditional 1-mm papillary lesion and a <1-mm focus of  in-
cipient papillary neoplasia (Fig. 6).
The patient had multiple followup MRIs of  the kidneys 
in the following years. Although the surgical margins were 
microscopically positive on the 2.2 and 1.0 cm tumors, nei-
ther showed radiographic evidence of  recurrence. A new, 
solid, enhancing left renal lesion was seen in October 2013,  
which was suspicious for neoplasm (Fig. 7). A positron emis-
sion tomography (PET) scan demonstrated this lesion to be 
fludeoxyglucose (FDG)-avid, with a standardized uptake 
value (SUV) of  4.9 (Fig. 8); it was new (as compared to the 
PET performed two years before). Around the same time, 
the patient’s family doctor also identified a cutaneous leio-
myoma, which was excised. Pathology showed minimal 
cytologic atypia and no mitotic activity but did show an 
infiltrative border, extending into subcutaneous fat (Fig. 9). 
In January 2014, left partial nephrectomies were per-
formed, yielding 4 renal tumors ranging in size from 0.6 to 
1.6 cm. These showed papillary and cribriform features, 
with focal areas showing marked nuclear pleomorphism. 
Multiple smaller (<1 mm) papillary lesions were also iden-
tified in the surrounding renal tissue.
A cancer geneticist confirmed a clinical diagnosis of  
HLRCC Syndrome. Genetic testing for a germline muta-
tion in the fumarate hydratase (FH) gene was positive. 
Physical findings supporting this diagnosis included the 
renal cancer, cutaneous leiomyoma, and history of  uterine 
leiomyomas.
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Figure 3. Right renal mass is present containing calcifica-
tions (CT without contrast, 2010).
Figure 2. Multiple cutaneous leiomyomas of varying size 
and shape on the patient's right flank.
Figure 4. Renal tumor showing tubular pattern with onco-
cytic cells (H&E, 400x).
Figure 5. Smaller tumor showing papillary type II morphol-
ogy (H&E, 400x)
Discussion
 HLRCC is an autosomal dominant (AD) condition in 
which individuals are predisposed to benign leiomyomas of  
the skin and uterus. In addition, such individuals are at 
increased risk for aggressive, early-onset renal-cell carci-
noma. The syndrome is caused by a germline mutation in 
the fumarate hydratase gene, which encodes for an enzyme 
in the citric acid cycle (1). At least 100 families have been 
identified worldwide with HLRCC, the majority being of  
Eastern European descent (2, 3). In a subset of  families 
with the germline FH mutation, over 75% had cutaneous 
leiomyomas, more than 60% had renal-cell carcinoma, and 
all of  the female carriers had uterine leiomyomas (3).
Patients may present with cutaneous leiomyomas, which 
are firm, tan to reddish-brown papules arising primarily 
from arrector pili muscles surrounding hair follicles. These 
lesions are often found on the trunk or extremities and can 
cause pain or paresthesias. Female patients normally de-
velop numerous, large, symptomatic uterine leiomyomas, 
occurring at an earlier age than in the general population; 
these often require hysterectomy. In addition to uterine 
leiomyomas, several patients have also developed leiomyo-
sarcomas (4). 
Cutaneous leiomyomas are rare in the general popula-
tion. Therefore, any patient who presents with these should 
undergo a thorough physical exam and history and be 
screened for renal tumors (3). Single cutaneous leiomyomas 
can be excised, but they commonly recur after removal. 
Cryotherapy and electrocoagulation may be considered 
with multiple lesions, but can cause extensive scarring (3, 
4). Female patients with HLRCC should be evaluated for 
uterine disease. Myomectomy can be performed in patients 
with uterine leiomyomas. Nevertheless, most of  the tumors 
are large and recurring, requiring hysterectomy. Any uter-
ine leiomyosarcomas should be removed via hysterectomy 
(4). Patients with confirmed renal tumors and FH germline 
mutations should be managed with surgical strategies due 
to the aggressive nature of  this renal cancer and the poten-
tial for early metastasis (1).  
Renal tumors in HLRCC have been reported to occur 
relatively early in life and behave aggressively. They typi-
cally present as a solitary unilateral mass, with multiple or 
bilateral tumors occurring infrequently (4). HLRCC most 
commonly shows type II papillary renal-cell carcinoma 
histology, but tubulopapillary, solid, collecting-duct, and 
mixed types have been reported (1, 5). Merino et al.  have 
described a series of  40 tumors in which the common his-
tological feature was large, inclusion-like nucleoli with per-
inucleolar haloes (6). 
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Figure 6. Renal tissue with incipient neoplasia (PAS, 400x).
Figure 7. New mass in the superior pole of the left kidney 
demonstrates heterogeneous enhancement (fat-saturated 
T1 post contrast, 2013).
Figure 8. Mass in the superior pole of the left kidney dem-
onstrates abnormally increased FDG uptake (FDG-PET, 
2013).
The pathologic findings in our case are unusual in several 
respects. Multiple synchronous primary tumors were found 
in both kidneys, with incipient neoplasia in the surrounding 
renal tissue. The tumors showed a range of  histologic pat-
terns, including oncocytic, solid, tubular, cribriform, and 
papillary. Perinucleolar haloes were 
inconspicuous. 
CT with and without contrast is the modality of  choice 
for kidney screening, as papillary renal cancers are often 
isoechoic on US, making them difficult to distinguish from 
the surrounding parenchyma (1, 7). Renal tumors often 
enhance 20 HU or more with addition of  contrast (1).  
However, noncontrast CT may pick up calcifications within 
the mass that would be obscured by contrast, as seen in this 
case (Fig. 3). In a subset of  HLRCC patients, the average 
tumor size was around 8 cm, with some as large as 20 cm. 
These tumors often metastasize to retroperitoneal and me-
diastinal lymph nodes, bones, and liver (1). 
Patients with HLRCC have a relatively poor prognosis, as  
the tumors are highly aggressive, metastasizing in approxi-
mately 50% of  patients (1). In one study, the 5-year survival 
rate of  patients with diagnosed renal-cell carcinoma was 
around 30%, with the cause of  death attributed to meta-
static disease (7). However, aggressive surgical treatment 
may significantly reduce the rate of  metastasis (1). Recent 
studies have shown optimistic results after employing 
pharmaceutical and molecular techniques to reduce aero-
bic glycolysis in tumor cells (8, 9). Inhibition of  lactate 
dehydrogenase-A in cells with an FH mutation significantly 
decreases tumor growth in a mouse model (8). The Na-
tional Institute of  Health (NIH) is currently performing a 
phase II study on the effect of  bevacizumab and erlotinib 
on metastatic renal cancer in HLRCC (10). These therapies 
may be used as first-line treatment of  HLRCC in the 
future.
In conclusion, HLRCC is a rare, AD condition that pre-
sents with cutaneous and uterine leiomyomas and renal-cell 
cancer. The degree of  renal involvement determines the 
prognosis of  the patient, as the renal cancers tend to be 
aggressive. CT is the preferred modality for kidney screen-
ing, as the tumors are isoechoic on US. Currently, this di-
agnosis carries a poor prognosis, but recent studies provide 
hope for better survival in the future.
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Figure 9. Cutaneous leiomyoma with infiltration of subcuta-
neous fat (Desmin, 100x).
